CNB Bank bought a new stake in Zimmer Biomet Holdings Inc (NYSE:ZBH) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 4,694 shares of the medical equipment provider’s stock, valued at approximately $566,000.
Several other institutional investors have also recently bought and sold shares of the company. We Are One Seven LLC acquired a new position in shares of Zimmer Biomet in the fourth quarter valued at approximately $137,000. APCM Wealth Management for Individuals acquired a new position in shares of Zimmer Biomet in the fourth quarter valued at approximately $231,000. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp grew its position in shares of Zimmer Biomet by 67.5% in the fourth quarter. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp now owns 100,000 shares of the medical equipment provider’s stock valued at $12,067,000 after purchasing an additional 40,300 shares during the last quarter. Wunderlich Capital Managemnt grew its position in shares of Zimmer Biomet by 6.9% in the fourth quarter. Wunderlich Capital Managemnt now owns 13,808 shares of the medical equipment provider’s stock valued at $1,666,000 after purchasing an additional 890 shares during the last quarter. Finally, Lincluden Management Ltd. grew its position in shares of Zimmer Biomet by 50.6% in the fourth quarter. Lincluden Management Ltd. now owns 93,839 shares of the medical equipment provider’s stock valued at $11,324,000 after purchasing an additional 31,530 shares during the last quarter. 86.49% of the stock is currently owned by institutional investors.
In other Zimmer Biomet news, VP Chad F. Phipps sold 20,826 shares of the firm’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $115.95, for a total value of $2,414,774.70. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Bryan C. Hanson bought 25,077 shares of Zimmer Biomet stock in a transaction on Tuesday, February 20th. The stock was acquired at an average cost of $119.68 per share, for a total transaction of $3,001,215.36. The disclosure for this purchase can be found here. Company insiders own 1.07% of the company’s stock.
ZBH has been the topic of several research reports. SunTrust Banks upped their target price on Zimmer Biomet to $142.00 and gave the company a “buy” rating in a research report on Monday, January 29th. Canaccord Genuity reissued a “hold” rating and set a $125.00 price target on shares of Zimmer Biomet in a research report on Tuesday, December 19th. Oppenheimer reissued a “buy” rating on shares of Zimmer Biomet in a research report on Tuesday, December 19th. BMO Capital Markets reissued a “buy” rating and set a $144.00 price target on shares of Zimmer Biomet in a research report on Tuesday, January 30th. Finally, Raymond James Financial began coverage on Zimmer Biomet in a research report on Thursday, March 15th. They set an “outperform” rating and a $135.00 price target on the stock. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $140.63.
Shares of Zimmer Biomet stock opened at $114.38 on Thursday. The firm has a market capitalization of $23,311.11, a price-to-earnings ratio of 12.69, a price-to-earnings-growth ratio of 2.00 and a beta of 1.13. Zimmer Biomet Holdings Inc has a twelve month low of $108.03 and a twelve month high of $133.49. The company has a quick ratio of 0.81, a current ratio of 1.50 and a debt-to-equity ratio of 0.76.
Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Tuesday, January 30th. The medical equipment provider reported $2.10 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $2.10. The firm had revenue of $2.07 billion for the quarter, compared to the consensus estimate of $2.03 billion. Zimmer Biomet had a return on equity of 15.45% and a net margin of 23.51%. The company’s revenue was up 3.0% compared to the same quarter last year. During the same quarter last year, the business posted $2.14 EPS. equities research analysts expect that Zimmer Biomet Holdings Inc will post 7.8 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Monday, April 30th. Shareholders of record on Thursday, March 29th will be issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.84%. The ex-dividend date is Wednesday, March 28th. Zimmer Biomet’s dividend payout ratio is presently 10.65%.
COPYRIGHT VIOLATION WARNING: This piece was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this piece on another website, it was illegally copied and reposted in violation of US & international copyright laws. The legal version of this piece can be read at https://ledgergazette.com/2018/03/22/cnb-bank-invests-566000-in-zimmer-biomet-holdings-inc-zbh.html.
About Zimmer Biomet
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.